Home Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers

IoT Medical Devices Market to Hit USD 239
Global Artificial Intelligence (AI) in Genomics Market Report 2023: Need to Accelerate Processes and Timeline and Reduce Drug Development & Discovery Costs Drives Growth